Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8

Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.